Condition: Recurrent Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Sponsor: Jonsson Comprehensive Cancer Center
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.
This description comes directly from the study's public registry record.
Gina A Khachatrian · 310 825-7028 · gkhachatrian@mednet.ucla.edu
Kimberly Kelly · 310-794-5517 · kmkelly@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04469764